Information Provided By: 
Fly News Breaks for April 19, 2017
POST
Apr 19, 2017 | 07:18 EDT
After Post Holdings agreed to buy Weetabix and Post's stock fell, SunTrust analyst William Chappell, Jr. says that the stock's decline was overblown. The analyst thinks that Post will exceed its GBP20M synergy target and has several positive catalysts in the next few months, including its Q2 report early next month and the closing of the Weetabix deal in early July. He raised his price target on Post to $105 from $95 and keeps a Buy rating on the shares.
News For POST From the Last 2 Days
There are no results for your query POST
